Inventor · disambiguated record
James Lorens
Also filed as: LORENS JAMES · LORENS JAMES B · LORENS JAMES BRADLEY
25 granted patents·20 pending applications·203 citations·filing 1998–2024
95Inventor score
Files withRIGEL PHARMACEUTICALS INC18BERGENBIO ASA8BERGEN TEKNOLOGIOVERFORING AS4BERGEN TEKNOLOGIOVERFOERING AS3LORENS JAMES B3
Top patents by PatentIndex Score
45 records- 0188US7252952B2In vivo production of cyclic peptides for inhibiting protein—protein interactionRIGEL PHARMACEUTICALS INC·Filed 2003·Granted Aug 7, 2007·19 cites·10 claims
- 0287US7378248B2In vivo production of cyclic peptides for inhibiting protein-protein interactionRIGEL PHARMACEUTICALS INC·Filed 2005·Granted May 27, 2008·7 cites·5 claims
- 0382US11198734B2Anti-Axl antagonistic antibodiesBERGEN TEKNOLOGIOVERFOERING ASA·Filed 2017·Granted Dec 14, 2021·3 cites·31 claims
- 0482US9040462B2In vivo production of cyclic peptides for inhibiting protein-protein interactionLORENS JAMES B·Filed 2008·Granted May 26, 2015·5 cites·18 claims
- 0582US8735064B2Methods for creating and identifying functional RNA interference elementsMICKLEM DAVID·Filed 2008·Granted May 27, 2014·7 cites·16 claims
- 0682US7419779B2Modulators of angiogenesisRIGEL PHARMACEUTICALS INC·Filed 2003·Granted Sep 2, 2008·8 cites·18 claims
- 0782US6391582B2Shuttle vectorsRIGEL PHARMACEUTICLAS INC·Filed 1998·Granted May 21, 2002·66 cites·3 claims
- 0881US7485414B2Modulators of angiogenesisRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Feb 3, 2009·8 cites·18 claims
- 0979US7527936B2Modulators of angiogenesisRIGEL PHARMACEUTICALS INC·Filed 2005·Granted May 5, 2009·7 cites·23 claims
- 1078US6645766B2Shuttle vectorsRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Nov 11, 2003·6 cites·4 claims
- 1177US7056687B2Methods and compositions for screening for altered cellular phenotypesRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Jun 6, 2006·4 cites·59 claims
- 1276US2023406941A1Anti-AXL Antagonistic AntibodiesBERGEN TEKNOLOGIOVERFOERING AS·Filed 2023·Application pending·0 cites
- 1375US11732048B2Anti-axl antagonistic antibodiesBERGEN TEKNOLOGIOVERFOERING AS·Filed 2021·Granted Aug 22, 2023·0 cites·20 claims
- 1475US7205130B2Bi-directionally cloned random cDNA expression vector libraries, compositions and methods of useRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Apr 17, 2007·3 cites·7 claims
- 1575US2024277707A1Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic VirusBERGENBIO ASA·Filed 2024·Application pending·0 cites
- 1674US2024190972A1Anti-Axl Antagonistic AntibodiesBERGEN TEKNOLOGIOVERFOERING AS·Filed 2023·Application pending·0 cites
- 1772US6280937B1Shuttle vectorsRIGEL PHARMACEUTICALS INC·Filed 1998·Granted Aug 28, 2001·34 cites·10 claims
- 1870US10208121B2Anti-Axl antagonistic antibodiesBERGEN TEKNOLOGIOVERFORING AS·Filed 2015·Granted Feb 19, 2019·1 cites·26 claims
- 1970US2023149397A1Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic VirusBERGENBIO ASA·Filed 2022·Application pending·0 cites
- 2067US11584796B2Anti-Axl antagonistic antibodiesBERGEN TEKNOLOGIOVERFORING AS·Filed 2018·Granted Feb 21, 2023·0 cites·17 claims
- 2162US2018246080A1Methods using axl as a biomarker of epithelial-to-mesenchymal transitionBERGEN TEKNOLOGIOVERFORING AS·Filed 2017·Application pending·0 cites
- 2261US2015212065A1Methods using Axl as a biomarker of epithelial-to-mesenchymal transitionBERGEN TEKNOLOGIOVERFORING AS·Filed 2014·Application pending·0 cites
- 2358US11534440B2Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virusBERGENBIO ASA·Filed 2020·Granted Dec 27, 2022·0 cites·18 claims
- 2458US9783801B2Methods for creating and identifying functional RNA interference elementsBERGENBIO ASA·Filed 2013·Granted Oct 10, 2017·0 cites·17 claims
- 2558US2013310278A1Multiparameter FACS Assays to Detect Alterations in Cellular Parameters and to Screen Small Molecule LibrariesRIGEL PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 2657US6461813B2Multiparameter FACS assays to detect alterations in cell cycle regulationRIGEL PHARMACEUTICALS INC·Filed 1998·Granted Oct 8, 2002·19 cites·11 claims
- 2756US2007105140A1In vivo production of cyclic peptidesLORENS JAMES B·Filed 2006·Application pending·0 cites
- 2855US2023372337A1Combination Therapy Comprising an AXL InhibitorBERGENBIO ASA·Filed 2021·Application pending·0 cites
- 2955US2007166769A1Bi-directionally cloned random cDNA expression vector libraries, compositions and methods of useLORENS JAMES·Filed 2007·Application pending·0 cites
- 3055US2007172818A1Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule librariesRIGEL PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 3154US2018153888A1Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virusBERGENBIO ASA·Filed 2016·Application pending·0 cites
- 3250US2006147978A1Methods and compositions for screening for altered cellular phenotypesLORENS JAMES·Filed 2006·Application pending·0 cites
- 3349US2023151100A1Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint ModulatorBERGENBIO ASA·Filed 2021·Application pending·0 cites
- 3449US2004005593A1Novel method for delivery and intracellular synthesis of siRNA moleculesRIGEL PHARMACEUTICALS INC·Filed 2003·Application pending·0 cites
- 3548US2023250169A1AXL Inhibitors for Antiviral TherapyBERGENBIO ASA·Filed 2021·Application pending·0 cites
- 3647US2012159655A1Methods using axl as a biomarker of epithelial-to-mesenchymal transitionLORENS JAMES BRADLEY·Filed 2010·Application pending·0 cites
- 3746US2004002056A1Methods of screening for bioactive agents using cells transformed with self-inactivating viral vectorsFiled 2002·Application pending·0 cites
- 3845US7566546B2Modulators of angiogenesis and tumorigenesisRIGEL PHARMACEUTICALS INC·Filed 2005·Granted Jul 28, 2009·0 cites·8 claims
- 3945US2003099932A1Retroviral vectors with separation sequencesFiled 2002·Application pending·0 cites
- 4041US2003176333A1CASPR3: modulators of angiogenesisRIGEL PHARMACEUTICALS INC·Filed 2002·Application pending·0 cites
- 4140US7244576B2Modulators of angiogenesisRIGEL PHARMACEUTICALS INC·Filed 2001·Granted Jul 17, 2007·0 cites·6 claims
- 4239US6897031B1Multiparameter FACS assays to detect alterations in exocytosisRIGEL PHARMACEUTICALS INC·Filed 1998·Granted May 24, 2005·6 cites·36 claims
- 4338US8574827B2Modulators of angiogenesis and tumorigenesisLORENS JAMES B·Filed 2003·Granted Nov 5, 2013·0 cites·13 claims
- 4431US6623980B1Exo1 and Exo2, exocytotic proteinsRIGEL PHARMACEUTICALS INC·Filed 1999·Granted Sep 23, 2003·0 cites·12 claims
- 4530US8334238B2Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule librariesFISHER JOSEPH·Filed 1999·Granted Dec 18, 2012·0 cites·8 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →